Medtronic plc

“Medtronic owns a genuinely defensible franchise — entrenched switching costs in CRM, neuromodulation, and structural heart, reinforced by hospital service infrastructure and regulatory scale — but a decade of evidence reveals a business that earns near-WACC returns on capital, consistently misses organic growth targets, carries a Covidien-era debt load that permanently impaired capital efficiency, and is the challenger (not the incumbent) in the fastest-growing segments. At 13x forward earnings and a 5% FCF yield it is cheap on any absolute measure, but the discount reflects structural reality: the business compounds at 7-9% annually in the base case, not the 12-15% needed to justify a premium. Without a visible inflection in organic growth or a demonstrable win in Hugo robotics or PulseSelect ablation, there is insufficient conviction to deploy capital when better compounders are available.”